Investor · 1 deal
Every published round Bill & Melinda Gates Foundation took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Nbryo | Seed | 11 Aug 2026 | $10m | Participant | nbryo.com, AgFunderNews, Startup Daily, Mandalay Venture Partners portfolio, Tenacious Ventures portfolio |
Companies Bill & Melinda Gates Foundation has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Nbryo | Queensland agtech startup focused on advanced reproductive technologies | 11 Aug 2026, Seed | 1 | 0 |
Fund closes reported for Bill & Melinda Gates Foundation, as distinct from the investments it has made.
Companies Bill & Melinda Gates Foundation has backed that another company then bought. An exit for the holding, not a deal Bill & Melinda Gates Foundation did.
Stories naming Bill & Melinda Gates Foundation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of a Sydney-based medical device maker developing a hydrogel condom, noting its human safety trial, manufacturing build-out, patent portfolio and grant backing.
Weekly roundup: Constantinople raises $62.5m; Blackbird wraps fund six above $1b; Guardhouse buys Mobohubb; SCX.ai debuts on the ASX; plus seed rounds, exits and executive changes across the ecosystem.
Roundup of four Australian raises: Firmus Technologies' US$2 billion round at a $15 billion valuation, Eudaemon's $3.75 million, Zabidou's $3.5 million seed round, and Rampart's $2.3 million.
Drone delivery company Swoop Aero has entered voluntary administration after its cofounder blamed investor pressure; administrators now seek a buyer or recapitalisation. The piece recalls its 2021 Series B and 2018 Startmate stint.
Also Startup Daily
Aura's column traces family offices' rise into major capital players, their philanthropy and succession challenges, and notes the closure of its Shippit co-investment vehicle plus Dan Annan's appointment as Distribution Director.
Tenacious Ventures' investment note explains its backing of Nbryo, an Australian startup speeding genetic improvement in beef and dairy via embryo technologies, and notes research funding from MLA and the Gates Foundation.
Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.
AgFunder's Asia-Pacific investment analysis finds agriculture-focused biotech surged in 2022, with China and India ahead, while Australian soil-carbon firm Loam Bio landed a sizable round in 2023.
Also AgFunderNews
Weekly agrifoodtech roundup: Paine Schwartz closes its $1.7bn food-and-ag fund; several seed and Series A rounds; Tangelo acquires Diet ID; Infarm declared bankrupt; layoffs and partnerships across the sector.
Brisbane vaccine patch maker Vaxxas won a $5.4 million Wellcome grant for studies and a Phase I trial of a typhoid vaccine using its HD-MAP technology, developed with SK bioscience.
Vaxxas, with Queensland Government backing, has opened its Brisbane global headquarters and vaccine patch manufacturing facility, supported by state and federal government funding.
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Vaxxas has appointed 23-year Pfizer veteran Dr Rochelle Chaiken as chief medical officer; the announcement also recaps the vaccine-patch company's early backing by OneVentures, Brandon Capital and others.
Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.
Also OneVentures portfolio·Brandon Capital portfolio·@AuManufacturing·SmartCompany·Techboard·@AuManufacturing
Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.
Brisbane biotech Vaxxas has begun human testing of its microneedle patch for COVID-19 vaccination and plans a phase two study; the venture-backed company has raised over $66 million.
Pfizer has completed its takeover of ASX-listed telehealth diagnostics company ResApp Health for $179 million, with the article recalling the company's 2015 listing, earlier raises and a Gates Foundation grant.
Pfizer has completed its purchase of Brisbane digital health company ResApp Health for $179 million, doubling its per-share offer after an April bid for the ASX-listed cough-diagnosis startup.
Also SmartCompany·Startup Daily·Startup Daily·Techboard·Startup News (WA)·sharecafe.com.au
NSW Government's 2016 Medical Devices Fund awarded $8.6 million to four medtech companies, Elastagen getting $4 million; earlier winners Saluda Medical and Atomo Diagnostics also feature, the latter having lately drawn Gates Foundation money.